IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME 4
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Mutations in CDCA7 and HELLS cause immunodeficiency-centromeric instability-facial anomalies syndrome.
|
26216346 |
2015 |
Immunodeficiency syndrome, variable
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
Mutations in CDCA7 and HELLS cause immunodeficiency-centromeric instability-facial anomalies syndrome.
|
26216346 |
2015 |
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Neoplasms
|
0.070 |
GeneticVariation
|
group |
BEFREE |
DNA-binding surface regions (L2, L3 and the LSH motif) and conserved regions (II-V), had significantly poorer prognoses than tumors with mutations outside of those regions.
|
12509970 |
2003 |
Neoplasm Metastasis
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
Decrease in Lymphoid Specific Helicase and 5-hydroxymethylcytosine Is Associated with Metastasis and Genome Instability.
|
29109788 |
2017 |
Malignant neoplasm of stomach
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome.
|
15254976 |
2004 |
Stomach Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome.
|
15254976 |
2004 |
IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME 4
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME 4
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Lsh is involved in de novo methylation of DNA.
|
16395332 |
2006 |
Adenocarcinoma of lung (disorder)
|
0.310 |
Biomarker
|
disease |
BEFREE |
The ratio of FoxA1 to FoxA2 in lung adenocarcinoma is regulated by LncRNA HOTAIR and chromatin remodeling factor LSH.
|
26658322 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.310 |
Biomarker
|
disease |
CTD_human |
c-Myc targeted regulators of cell metabolism in a transgenic mouse model of papillary lung adenocarcinoma.
|
27602772 |
2016 |
Immunodeficiency syndrome, variable
|
0.310 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Lsh is involved in de novo methylation of DNA.
|
16395332 |
2006 |
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
Polycystic Ovary Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles.
|
21411543 |
2011 |
Sclerocystic Ovaries
|
0.300 |
Biomarker
|
disease |
CTD_human |
Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles.
|
21411543 |
2011 |
Agammaglobulinemia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Anemia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Communicating Hydrocephalus
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Dwarfism
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Orbital separation excessive
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Lymphopenia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Macroglossia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Malabsorption Syndrome
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Micrognathism
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|